AssetMark Inc
NVCR icon

AssetMark Inc’s NovoCure NVCR Stock Holding History

AssetMark Inc’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14
Closed -$249 – 3243
2025
Q2 		$249 Buy
+14
New +$244 ﹤0.01% 2852
2023
Q4 		– Sell
-7,166
Closed -$116K – 1965
2023
Q3 		$116K Buy
7,166
+1,938
+37% +$55.9K ﹤0.01% 957
2023
Q2 		$217K Buy
5,228
+586
+13% +$36.4K ﹤0.01% 834
2023
Q1 		$279K Sell
4,642
-1,842
-28% -$147K ﹤0.01% 788
2022
Q4 		$476K Buy
6,484
+802
+14% +$60.3K ﹤0.01% 710
2022
Q3 		$432K Buy
5,682
+1,295
+30% +$101K ﹤0.01% 673
2022
Q2 		$305K Buy
4,387
+917
+26% +$69.1K ﹤0.01% 692
2022
Q1 		$287K Buy
3,470
+1,800
+108% +$133K ﹤0.01% 695
2021
Q4 		$125K Buy
1,670
+1,606
+2,509% +$161K ﹤0.01% 768
2021
Q3 		$7K Buy
+64
New +$9.68K ﹤0.01% 1094
2020
Q1 		– Sell
-14
Closed -$1K – 1486
2019
Q4 		$1K Hold
14
– – ﹤0.01% 1327
2019
Q3 		$1K Buy
+14
New +$1.12K ﹤0.01% 1253

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AssetMark Inc's NVCR Position: Q3 2025 in Review

AssetMark Inc sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 14 shares — an estimated $249 sold.

AssetMark Inc first reported a position in NVCR in Q3 2019 and held it in 12 quarters. The position peaked at $476K in Q4 2022. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • AssetMark Inc reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • AssetMark Inc sold 14 NovoCure shares in Q3 2025, an estimated $249.
  • AssetMark Inc first reported a position in NovoCure in Q3 2019 and held it in 12 quarters.
  • AssetMark Inc's NovoCure position peaked at $476K in Q4 2022.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on AssetMark Inc's 13F filing for Q3 2025, filed 6 Nov 2025.